SQZ Biotech Announces Pricing of Initial Public Offering

WATERTOWN, Mass.–(BUSINESS WIRE)–SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) today announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by SQZ. In addition, SQZ has granted the underwriters a 30-day option to … [Read more…]

Andrew Holman Joins Prytime Medical as Chief Commercialization Officer

SAN ANTONIO–(BUSINESS WIRE)–#reboa–Prytime Medical Devices, Inc. announced that Andrew Holman has joined the company as Chief Commercialization Officer effective October 26, 2020. Holman has more than 20 years of senior management experience, including strategic development and commercial execution in medical devices, most recently as Global President, Q Medical Devices. Prior to that, he served as … [Read more…]

New Study Shows Use of NeurOptics’ Automated Pupillometry Improves Triage for Patients with Traumatic Brain Injury

NPi-200 Pupillometer Measures Pupillary Light Reflex to Identify Patients who Require Immediate Treatment, Expediting Care LAGUNA HILLS, Calif.–(BUSINESS WIRE)–A new study published in the journal World Neurosurgery demonstrated that automated infrared pupillometry can improve triage and expedite treatment for patients with traumatic brain injuries. Automated infrared pupillometry is an objective assessment of the pupillary light … [Read more…]

California Leafy Greens Marketing Agreement Announces Tim York As New CEO

SACRAMENTO, Calif.–(BUSINESS WIRE)–Tim York was named as the new Chief Executive Officer of the California Leafy Greens Marketing Agreement (LGMA) during today’s Board of Directors meeting. York will replace Scott Horsfall who is retiring in early 2021. “Tim has been an influential presence when it comes to advancing continuous improvement in food safety in the … [Read more…]

Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP

LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN™¥. “Nexus Pharmaceuticals is very pleased to announce the approval of Succinylcholine Chloride. This critical need drug has seen an increased demand due to the … [Read more…]

The Region’s Life Science Industry: Accelerating Discovery and Diversity at #OregonBioDigital

PORTLAND, Ore.–(BUSINESS WIRE)–#BioPro–How the Pacific Northwest accelerates and amplifies the growth and diversity of our life science and biotech clusters will be under the microscope at the Oregon Bio Digital 2020: Amplifying Diversity of Discovery, Access and Economics Conference. Happening over three half-days, November 17, 18 and 19, the event will bring together investors, start-up … [Read more…]

Geron to Announce Third Quarter Financial Results on November 5, 2020

FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as … [Read more…]

Invacare Reports Results for Third Quarter 2020

Achieved sequential improvement in net sales and profitability Increases full year 2020 guidance for net sales and Adjusted EBITDA Retired $24.5 million of convertible notes due in 2021 ELYRIA, Ohio–(BUSINESS WIRE)–Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) today reported results for the quarter ended September 30, 2020. Key Metrics (3Q20 versus 3Q19, except as … [Read more…]

Seagen Reports Third Quarter 2020 Financial Results

-Net Product Sales $267.5 Million in 3Q20, an Increase of 60 Percent Over 3Q19- -Collaborations with Merck for Ladiratuzumab Vedotin and TUKYSA; Seagen Received $725M in Upfront Payments and $1B Equity Investment- -Positive Data from Two PADCEV Clinical Trials to Support Global Registration Applications and Expand U.S. Indication- -Positive Data from Tisotumab Vedotin Pivotal Trial; … [Read more…]

Cerus Corporation Announces Record Third Quarter 2020 Results

CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include: Q3 2020 Total Revenue of $29.2 million – driven by significant year-over-year platelet kit sales growth in the U.S. as well as plasma and platelet kit sales from the EMEA region. Total … [Read more…]